naltrexone has been researched along with Depressive Disorder, Major in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 9 (26.47) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, CA; Lucki, I; Wulf, HA; Zarate, CA | 1 |
| Glover, SC; Hoeh, NR; Lin, JC; Moloney, BD; Muthukumaraswamy, S; Plank, JR; Sumner, RL; Sundram, F | 1 |
| Lambeth, PS; Margolis, EB; Moulton, MG; O'Meara, MJ | 1 |
| Eitan, S; Madison, CA | 1 |
| Muvvala, SB; O'Malley, SS; Rosenheck, R | 1 |
| Chen, J; Dombrovski, AY; Karp, JF; Lyew, T; Peciña, M | 1 |
| Chai, JR; Du, WJ; Guo, LB; Li, QL; Liu, JG; Liu, R; Liu, ZQ; Sun, X; Wang, CY; Wang, YJ; Zan, GY | 1 |
| Anderson, PM; Hillhouse, TM; Kegen, TN; Koppenhaver, PO; Lane, JT; Manicka, SG; Porter, JH; Pottanat, E; Rice, R; Van Fossen, M; Zhang, F | 1 |
| Dunayevich, E; Guerdjikova, AI; Halseth, AE; McElroy, SL; Shan, K; Walsh, B | 1 |
| Ho, RC; McIntyre, RS; Ragguett, RM; Rong, C; Rosenblat, JD | 1 |
| Arnelle, D; Bidlack, JM; Deaver, DR; Fern Toh, M; Knapp, BI; Namchuk, MN; Pin, SS; Plotnikava, M; Wonsey, AM | 1 |
| Ehrich, E; Fava, M; Martin, WF; Memisoglu, A; Nangia, N; Pathak, S; Stanford, AD; Thase, ME; Trivedi, MH; Yu, M | 1 |
| Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Sanchez, C; Smith, KL | 1 |
| Krystal, JH; Petrakis, IL; Yoon, G | 1 |
| Beaglehole, B; Boden, JM; Foulds, J; Mulder, RT | 1 |
| Bodkin, JA; Claxton, A; Fava, M; Martin, W; Memisoglu, A; Pathak, S; Stanford, AD; Thase, ME; Trivedi, MH; Yu, M | 1 |
| Du, Y; Ehrich, E; Fava, M; Fernandez, E; Jones, R; Leigh-Pemberton, R; Turncliff, R | 1 |
| Adamson, SJ; Boden, JM; Douglas Sellman, J; Foulds, JA; Joyce, PR; Mulder, RT | 1 |
| Adamson, SJ; Berks, J; Cape, G; Deering, D; Dunn, A; Foulds, JA; Frampton, CM; Nixon, L; Sellman, JD | 1 |
| Adamson, SJ; Foulds, JA; Kennedy, MA; Mulder, RT; Sellman, JD; Ton, K | 1 |
| Helton, SG; Lohoff, FW | 1 |
| Bodkin, JA; de Somer, M; DiPetrillo, L; Du, Y; Ehrich, E; Fava, M; Leigh-Pemberton, R; Memisoglu, A; Silverman, B; Thase, ME; Trivedi, MH | 1 |
| Alpert, JE; Baer, L; Clain, AJ; Cusin, C; Fava, M; Hylek, L; Ionescu, DF; Mischoulon, D; Soskin, DP; Yeung, AS | 1 |
| Le Foll, B; Samokhvalov, AV | 1 |
| Drummond, PD; Frew, AK | 2 |
| Dackis, CA; Dundon, WD; Gallis, TL; Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Xie, H | 1 |
| Li, TK; Patkar, AA | 1 |
| Dundon, WD; O'Brien, CP; Pettinati, HM | 1 |
| Grant, JE; Grosz, R | 1 |
| Bonnet, U; Overlack, M; Schürks, M | 1 |
| Oslin, DW | 1 |
| Sher, L | 1 |
| Carroll, K; Levinson, C; Nich, C; Petrakis, I; Poling, J; Ralevski, E; Rounsaville, B | 1 |
6 review(s) available for naltrexone and Depressive Disorder, Major
| Article | Year |
|---|---|
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.
Topics: Alcoholism; Analgesics, Opioid; Depressive Disorder, Major; Humans; Naltrexone; Narcotic Antagonists; Opioid Peptides; Opioid-Related Disorders | 2023 |
Buprenorphine: prospective novel therapy for depression and PTSD.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Prospective Studies; Stress Disorders, Post-Traumatic; Young Adult | 2020 |
Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; Naltrexone; Treatment Outcome | 2018 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States | 2015 |
Current status of co-occurring mood and substance use disorders: a new therapeutic target.
Topics: Alcoholism; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Therapy, Combination; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Psychotropic Drugs; Sertraline; Substance-Related Disorders | 2013 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; Depressive Disorder, Major; Humans; Hydroxyindoleacetic Acid; Naltrexone; Narcotic Antagonists; Personality Disorders; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicide; Suicide, Attempted; Taurine | 2006 |
16 trial(s) available for naltrexone and Depressive Disorder, Major
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Topics: Anti-Inflammatory Agents; Australia; Biomarkers; C-Reactive Protein; Depressive Disorder, Major; Double-Blind Method; Humans; Inflammation; Naltrexone; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement.
Topics: Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Humans; Naltrexone; Narcotic Antagonists; Placebo Effect; Prefrontal Cortex | 2021 |
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Topics: Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Treatment Outcome | 2020 |
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Naltrexone; Pilot Projects | 2019 |
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Treatment Outcome | 2019 |
Evaluation of opioid modulation in major depressive disorder.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Cohort Studies; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2015 |
Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors.
Topics: Adolescent; Adult; Aged; Alcoholism; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Treatment Outcome; Young Adult | 2015 |
A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
Topics: Adult; Affect; Alcoholism; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
Topics: Alcoholism; Depressive Disorder, Major; Female; Genotype; Humans; Male; Naltrexone; Polymorphism, Single Nucleotide; Receptors, Opioid, mu | 2015 |
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2016 |
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Topics: Adult; Antidepressive Agents; Aripiprazole; Central Nervous System Stimulants; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Sertraline; Treatment Outcome | 2017 |
Stress-evoked opioid release inhibits pain in major depressive disorder.
Topics: Adult; Analgesics, Opioid; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Pain; Placebo Effect; Stress, Psychological | 2008 |
Opposite effects of opioid blockade on the blood pressure-pain relationship in depressed and non-depressed participants.
Topics: Adolescent; Adult; Blood Pressure; Cold Temperature; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pain; Pain Threshold; Time Factors; Young Adult | 2009 |
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
Topics: Adult; Alcoholism; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Treatment of late-life depression complicated by alcohol dependence.
Topics: Age of Onset; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Empathy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sertraline; Social Support | 2005 |
Naltrexone and disulfiram in patients with alcohol dependence and current depression.
Topics: Alcohol Deterrents; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Comorbidity; Connecticut; Depressive Disorder, Major; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Gastrointestinal Diseases; Humans; Male; Massachusetts; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2007 |
12 other study(ies) available for naltrexone and Depressive Disorder, Major
| Article | Year |
|---|---|
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Humans; Ketamine; Mice; Naltrexone; Receptors, Opioid, kappa | 2022 |
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Depressive Disorder, Major; Female; Hospitalization; Humans; Ill-Housed Persons; Male; Mental Health Services; Middle Aged; Morbidity; Naltrexone; Psychotherapy; Psychotropic Drugs; Schizophrenia; Socioeconomic Factors; United States; United States Department of Veterans Affairs; Veterans | 2021 |
Amygdala dynorphin/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress.
Topics: Amygdala; Animals; Behavior, Animal; Depressive Disorder, Major; Dynorphins; Extracellular Signal-Regulated MAP Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Proto-Oncogene Proteins c-fos; Receptors, Opioid, kappa; Social Behavior; Social Defeat | 2022 |
Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Hindlimb Suspension; Ketamine; Locomotion; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Psychomotor Agitation; Receptors, Opioid | 2021 |
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bupropion; Comorbidity; Depressive Disorder, Major; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight | 2017 |
In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
Topics: Animals; beta-Arrestins; Buprenorphine; Cell Line; CHO Cells; Cricetulus; Depressive Disorder, Major; Drug Combinations; GTP-Binding Proteins; HEK293 Cells; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Receptors, Opioid, mu | 2018 |
Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Citalopram; Depressive Disorder, Major; Dopamine; Drug Combinations; Drug Therapy, Combination; Male; Models, Animal; Motor Activity; Naltrexone; Rats; Rats, Inbred WKY; Serotonin; Swimming | 2019 |
Dispensing of medication for alcohol use disorder; an examination of large databases in a New Zealand context.
Topics: Alcohol Deterrents; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; New Zealand; Quetiapine Fumarate | 2019 |
A 35-year-old woman with low mood and concerns about her alcohol use.
Topics: Adult; Alcoholism; Antidepressive Agents; Counseling; Depressive Disorder, Major; Female; Humans; Naltrexone; Narcotic Antagonists; Patient Care Planning; Sertraline | 2017 |
Treatments for alcohol dependence: rethinking the role of comorbidity and clinical subtypes.
Topics: Alcoholism; Cognitive Behavioral Therapy; Comorbidity; Depressive Disorder, Major; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Pharmacotherapy outcome in older pathological gamblers: a preliminary investigation.
Topics: Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Gambling; Humans; Male; Middle Aged; Naltrexone; Personality Assessment; Phobic Disorders; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.
Topics: Alcoholism; Amitriptyline; Depressive Disorder, Major; Ethanol; Humans; Male; Middle Aged; Morphine; Morphine Dependence; Naltrexone; Narcotics; Severity of Illness Index; Substance Withdrawal Syndrome | 2005 |